Skip to main content
main-content

Zeitschrift

Clinical Pharmacokinetics

Clinical Pharmacokinetics 2/2020

Ausgabe 2/2020

Inhaltsverzeichnis ( 15 Artikel )

26.10.2019 | Review Article | Ausgabe 2/2020

Drug Exposure to Establish Pharmacokinetic–Response Relationships in Oncology

Belén P. Solans, María Jesús Garrido, Iñaki F. Trocóniz

02.11.2019 | Review Article | Ausgabe 2/2020

Clinical Pharmacokinetics and Pharmacodynamics of Etravirine: An Updated Review

Joshua P. Havens, Anthony T. Podany, Kimberly K. Scarsi, Courtney V. Fletcher

30.10.2019 | Review Article | Ausgabe 2/2020 Open Access

Fast-Acting Insulin Aspart: A Review of its Pharmacokinetic and Pharmacodynamic Properties and the Clinical Consequences

Hanne Haahr, Tim Heise

20.08.2019 | Systematic Review | Ausgabe 2/2020 Open Access

Pharmacokinetics and Target Attainment of Antibiotics in Critically Ill Children: A Systematic Review of Current Literature

Stan J. F. Hartman, Roger J. Brüggemann, Lynn Orriëns, Nada Dia, Michiel F. Schreuder, Saskia N. de Wildt

16.07.2019 | Original Research Article | Ausgabe 2/2020

A Semi-Mechanistic Population Pharmacokinetic/Pharmacodynamic Model of Bortezomib in Pediatric Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

Julie M. Janssen, T. P. C. Dorlo, D. Niewerth, A. J. Wilhelm, C. M. Zwaan, J. H. Beijnen, A. Attarbaschi, A. Baruchel, F. Fagioli, T. Klingebiel, B. De Moerloose, G. Palumbo, A. von Stackelberg, G. J. L. Kaspers, A. D. R. Huitema

22.07.2019 | Original Research Article | Ausgabe 2/2020 Open Access

Population Pharmacokinetics of an Anti-PD-L1 Antibody, Durvalumab in Patients with Hematologic Malignancies

Ken Ogasawara, Kathryn Newhall, Stephen E. Maxwell, Justine Dell’Aringa, Vitalina Komashko, Nurgul Kilavuz, Richard Delarue, Myron Czuczman, Lars Sternas, Shelonitda Rose, C. L. Beach, Steven Novick, Simon Zhou, Maria Palmisano, Yan Li

20.08.2019 | Original Research Article | Ausgabe 2/2020

Population Pharmacokinetics of Apalutamide and its Active Metabolite N-Desmethyl-Apalutamide in Healthy and Castration-Resistant Prostate Cancer Subjects

Carlos Pérez-Ruixo, Jonás Samuel Pérez-Blanco, Caly Chien, Margaret Yu, Daniele Ouellet, Juan-José Pérez-Ruixo, Oliver Ackaert

22.08.2019 | Original Research Article | Ausgabe 2/2020

Development and Validation of a Population-Pharmacokinetic Model for Rurioctacog Alfa Pegol (Adynovate®): A Report on Behalf of the WAPPS-Hemo Investigators Ad Hoc Subgroup

Pierre Chelle, Cindy H. T. Yeung, Stacy E. Croteau, Jennifer Lissick, Vinod Balasa, Christina Ashburner, Young Shil Park, Santiago Bonanad, Juan Eduardo Megías-Vericat, Azusa Nagao, Tung Wynn, Fernando Corrales-Medina, Huyen Tran, Anjali Sharathkumar, Meera Chitlur, Samuel Sarmiento, Andrea Edginton, Alfonso Iorio

21.08.2019 | Original Research Article | Ausgabe 2/2020 Open Access

Population Pharmacokinetics of Intravenous Salbutamol in Children with Refractory Status Asthmaticus

Nienke J. Vet, Brenda C. M. de Winter, Muriel Koninckx, Shelley A. Boeschoten, Annemie L. M. Boehmer, Jacintha T. Verhallen, Frans B. Plötz, Anja A. Vaessen-Verberne, Bart C. H. van der Nagel, Catherijne A. J. Knibbe, Corinne M. P. Buysse, Saskia N. de Wildt, Birgit C. P. Koch, Matthijs de Hoog

05.12.2019 | Letter to the Editor | Ausgabe 2/2020 Open Access

Comment on: “Why Were More Than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?”

Axel Krebs-Brown, Alain Munafo, Sumedh Gaikwad, Bogumila Urgatz, Claire Castello-Bridoux

05.12.2019 | Letter to the Editor | Ausgabe 2/2020 Open Access

Authors’ Reply to Krebs-Brown et al. Comment on: “Why Were More Than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?”

D. Concordet, P. Gandia, J. L. Montastruc, A. Bousquet-Mélou, P. Lees, A. A. Ferran, P. L. Toutain

05.12.2019 | Letter to the Editor | Ausgabe 2/2020

Comment on: “Why Were More Than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?”

Patrick Nicolas

05.12.2019 | Letter to the Editor | Ausgabe 2/2020 Open Access

Authors’ Reply to Nicolas: “Why Were More than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?”

Didier Concordet, Peggy Gandia, Jean-Louis Montastruc, Alain Bousquet-Mélou, Peter Lees, Aude A. Ferran, Pierre-Louis Toutain

05.12.2019 | Letter to the Editor | Ausgabe 2/2020

Comment on “Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?”

Yang Yu, Marc Maliepaard

05.12.2019 | Letter to the Editor | Ausgabe 2/2020 Open Access

Authors’ Reply to Yu et al.: “Levothyrox® New and Old Formulations: Are They Switchable for Millions of Patients?”

Didier Concordet, Peggy Gandia, Jean-Louis Montastruc, Alain Bousquet-Mélou, Peter Lees, Aude A. Ferran, Pierre-Louis Toutain

Aktuelle Ausgaben